AimedBio Debuts on KOSDAQ with USD 2 Billion Market Cap, Shares Surge 300%
2025.12.04
- AimedBio made its KOSDAQ debut on November 4, with its share price surging 300% on the first trading day, reaching a market capitalization of approximately USD 2 billion.
- The company achieved the largest KOSDAQ IPO of 2025, reflecting strong investor demand.
- During institutional bookbuilding, Aimed Bio recorded an 80.2% lock-up commitment rate, with more than 50% of allocations committed for at least three months. Its retail offering attracted approximately USD 11 billion in subscription deposits.
- Founded in 2018 as a spin-off from Samsung Medical Center, AimedBio has established a differentiated ADC platform based on patient-derived models and clinical data, securing major licensing and collaboration agreements with Biohaven and Boehringer Ingelheim totaling more than USD 2.1 billion while still privately held.
- The IPO proceeds will be used to accelerate R&D for existing and new pipelines, strengthen in-house clinical development capabilities, and support the company's transition from a preclinical partnering biotech to one capable of conducting independent clinical development.
